Fujifilm Launches Fujifilm Diosynth Biotechnologies

The former Merck BioManufacturing Network has been named Fujifilm Diosynth Biotechnologies following the completion of FUJIFILM Corp.’s recent acquisition of the company. The acquisition includes the facilities located in Billingham, UK (MSD Biologics Ltd., formerly Avecia Biologics) and Research Triangle Park, NC (Diosynth RTP LLC).

Yuzo Toda, general manager of Pharmaceutical Products Division, FUJIFILM Corp., said, “We are delighted to complete the addition of this business to Fujifilm’s growing portfolio of healthcare and life science businesses. We intend that Fujifilm Diosynth Biotechnologies will lead the global Biologics CMO industry through continuous innovation of technologies, service delivery and quality, contributing to the enhancement of the quality of life of people worldwide. Key to this is the very talented and experienced workforce at both Billingham and RTP, backed by world-leading technologies and first-class manufacturing assets.”

Steve Bagshaw, managing director, Fujifilm Diosynth Biotechnologies, Billingham UK, added, “This transition of ownership to Fujifilm, and closer collaboration with our U.S. colleagues in NC will truly position us as a world leading contract biologics development and manufacturing business. We look forward to working with both existing and new customers to help bring their drug developments to market.”